Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


No Brexit Fall Out For UK FIH Trials With Over 40% Jump In Applications

Executive Summary

Despite Brexit, the UK is still seen as an attractive place to do clinical research, according to the Medicines and Healthcare products Regulatory Agency. However, the agency's involvement in the EU Voluntary Harmonization Procedure has taken a hit. 

You may also be interested in...

UK Insists No Brexit Impact On Clinical Trial Rates

The UK insists there have been no major changes to the clinical trial environment since the country voted to leave the EU more than three years ago. It says the country continues to be an attractive location for clinical research.

UK Smooths Clinical Trial Pathway To Reassure Companies With Brexit Jitters

The UK is revising its clinical trial processes to align them with the new EU Clinical Trials Regulation so that companies can seek authorization just as easily in the UK as in other EU member states, irrespective of the situation after Brexit.

UK Promises ‘Competitive’ Clinical Trial Process Whatever The Brexit Outcome

The UK pharmaceutical industry has welcomed government guidance on the clinical trial regulatory landscape after Brexit, as well as a report from Cancer Research UK on the need to preserve alignment with the EU’s Clinical Trial Regulation.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts